|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5804381A
(en)
|
1996-10-03 |
1998-09-08 |
Cornell Research Foundation |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US6235525B1
(en)
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
|
UA56132C2
(uk)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
EP0871747A1
(en)
|
1996-01-02 |
1998-10-21 |
Chiron Viagene, Inc. |
Immunostimulation mediated by gene-modified dendritic cells
|
|
EP0895538B1
(en)
|
1996-04-19 |
2002-07-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
|
|
DE69723434T2
(de)
|
1996-04-26 |
2004-05-19 |
Rijksuniversiteit Te Leiden |
Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
|
|
EP0938298B1
(en)
|
1996-09-13 |
2002-12-04 |
Lipoxen Technologies Limited |
Liposome-based composition
|
|
EP0839912A1
(en)
|
1996-10-30 |
1998-05-06 |
Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) |
Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
|
|
US6074645A
(en)
|
1996-11-12 |
2000-06-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
|
WO1999024566A1
(en)
|
1997-11-06 |
1999-05-20 |
Roche Diagnostics Gmbh |
Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
|
|
WO1999034015A2
(en)
|
1997-12-24 |
1999-07-08 |
Imperial Cancer Research Technology Limited |
Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
|
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
|
JP2002526421A
(ja)
|
1998-10-05 |
2002-08-20 |
ジェンザイム・コーポレーション |
癌細胞に差別的に発現する癌ワクチン設計のための遺伝子
|
|
KR100773109B1
(ko)
|
1999-05-06 |
2007-11-02 |
웨이크 포리스트 유니버시티 |
면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
|
|
EP1261704B1
(en)
|
1999-11-30 |
2009-07-01 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
|
|
US7462354B2
(en)
|
1999-12-28 |
2008-12-09 |
Pharmexa Inc. |
Method and system for optimizing minigenes and peptides encoded thereby
|
|
AU780064B2
(en)
|
1999-12-28 |
2005-02-24 |
Epimmune, Inc. |
Optimized minigenes and peptides encoded thereby
|
|
EP1292331A2
(en)
|
2000-06-07 |
2003-03-19 |
Biosynexus Incorporated |
Immunostimulatory rna/dna hybrid molecules
|
|
EP1363938B1
(en)
|
2000-08-03 |
2013-12-11 |
Johns Hopkins University |
Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
|
|
US6472176B2
(en)
|
2000-12-14 |
2002-10-29 |
Genvec, Inc. |
Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
|
|
ATE291925T1
(de)
|
2001-06-05 |
2005-04-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
AUPS054702A0
(en)
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
|
ATE519115T1
(de)
|
2002-06-13 |
2011-08-15 |
Merck Patent Gmbh |
Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
DE10344799A1
(de)
|
2003-09-26 |
2005-04-14 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
WO2005039533A1
(en)
|
2003-10-15 |
2005-05-06 |
Medigene Ag |
Method of administering cationic liposomes comprising an active drug
|
|
BRPI0415533A
(pt)
|
2003-10-24 |
2006-12-26 |
Immunaid Pty Ltd |
método de terapia
|
|
US7303881B2
(en)
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
|
DE102004023187A1
(de)
|
2004-05-11 |
2005-12-01 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
GB2434367B
(en)
*
|
2004-10-05 |
2010-05-12 |
Diversa Corp |
Improved vaccines
|
|
DE102004057303A1
(de)
|
2004-11-26 |
2006-06-01 |
Merck Patent Gmbh |
Stabile Kristallmodifikationen von DOTAP Chlorid
|
|
EP1838342A2
(en)
|
2004-12-29 |
2007-10-03 |
Mannkind Corporation |
Methods to bypass cd+4 cells in the induction of an immune response
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
DE102005041616B4
(de)
|
2005-09-01 |
2011-03-17 |
Johannes-Gutenberg-Universität Mainz |
Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
|
|
EP1762575A1
(en)
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated antigens for diagnosis and therapy
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
JP2009532664A
(ja)
|
2006-02-27 |
2009-09-10 |
アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ |
癌の治療のためのノボペプチドの同定および使用
|
|
JP2010504356A
(ja)
|
2006-09-20 |
2010-02-12 |
ザ ジョンズ ホプキンス ユニバーシティー |
抗b7−h1抗体を用いた癌及び感染性疾患の組合せ療法
|
|
DE102006060824B4
(de)
|
2006-12-21 |
2011-06-01 |
Johannes-Gutenberg-Universität Mainz |
Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
|
|
CA2673870A1
(en)
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
|
US8140270B2
(en)
|
2007-03-22 |
2012-03-20 |
National Center For Genome Resources |
Methods and systems for medical sequencing analysis
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
EP2060583A1
(en)
|
2007-10-23 |
2009-05-20 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated markers for diagnosis and therapy
|
|
KR101606219B1
(ko)
|
2008-03-24 |
2016-03-24 |
4에스체 악티엔게젤샤프트 |
신규 치환된 이미다조퀴놀린
|
|
AU2009236306B2
(en)
|
2008-04-17 |
2015-04-02 |
Pds Biotechnology Corporation |
Stimulation of an immune response by enantiomers of cationic lipids
|
|
US20110195090A1
(en)
*
|
2008-10-11 |
2011-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Method of making a vaccine
|
|
DE102008061522A1
(de)
|
2008-12-10 |
2010-06-17 |
Biontech Ag |
Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
|
|
AU2010234362B2
(en)
*
|
2009-04-08 |
2015-11-26 |
Alphavax, Inc. |
Alphavirus replicon particles expressing TRP2
|
|
EA022786B1
(ru)
|
2009-07-31 |
2016-03-31 |
Этрис Гмбх |
Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
|
|
US9115402B2
(en)
|
2010-05-14 |
2015-08-25 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of identifying tumor specific neoantigens
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
NZ616304A
(en)
*
|
2011-04-08 |
2016-01-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
DE102011102734A1
(de)
|
2011-05-20 |
2012-11-22 |
WMF Württembergische Metallwarenfabrik Aktiengesellschaft |
Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
|
|
LT2714071T
(lt)
*
|
2011-05-24 |
2019-10-10 |
Biontech Rna Pharmaceuticals Gmbh |
Individualizuotos vakcinos nuo vėžio
|
|
WO2012159643A1
(en)
*
|
2011-05-24 |
2012-11-29 |
Biontech Ag |
Individualized vaccines for cancer
|
|
EP2771349B1
(en)
|
2011-09-16 |
2020-02-26 |
Iogenetics, LLC. |
Bioinformatic processes for determination of peptide binding
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
WO2013106496A1
(en)
|
2012-01-10 |
2013-07-18 |
modeRNA Therapeutics |
Methods and compositions for targeting agents into and across the blood-brain barrier
|
|
WO2013124701A2
(en)
|
2012-02-20 |
2013-08-29 |
Universita' Degli Studi Di Milano |
New homo- and heterodimeric smac mimetic compounds as apoptosis inducers
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
US20130255281A1
(en)
|
2012-03-29 |
2013-10-03 |
General Electric Company |
System and method for cooling electrical components
|
|
MX364370B
(es)
|
2012-07-12 |
2019-04-24 |
Persimmune Inc |
Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
CA2890110C
(en)
|
2012-11-01 |
2023-05-02 |
Factor Bioscience Inc. |
Methods and products for expressing proteins in cells
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
AU2013351542B2
(en)
|
2012-11-28 |
2018-08-09 |
BioNTech SE |
Individualized vaccines for cancer
|
|
WO2014164253A1
(en)
|
2013-03-09 |
2014-10-09 |
Moderna Therapeutics, Inc. |
Heterologous untranslated regions for mrna
|
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
WO2014144711A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
|
EP2971033B8
(en)
|
2013-03-15 |
2019-07-10 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
US10077439B2
(en)
|
2013-03-15 |
2018-09-18 |
Modernatx, Inc. |
Removal of DNA fragments in mRNA production process
|
|
EP4279610A3
(en)
|
2013-03-15 |
2024-01-03 |
ModernaTX, Inc. |
Ribonucleic acid purification
|
|
AU2014251207B2
(en)
|
2013-04-07 |
2019-06-13 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for personalized neoplasia vaccines
|
|
WO2015014375A1
(en)
|
2013-07-30 |
2015-02-05 |
Biontech Ag |
Tumor antigens for determining cancer therapy
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
CA2923029A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015038892A1
(en)
|
2013-09-13 |
2015-03-19 |
Moderna Therapeutics, Inc. |
Polynucleotide compositions containing amino acids
|
|
EP3049065A1
(en)
|
2013-09-26 |
2016-08-03 |
BioNTech AG |
Particles comprising a shell with rna
|
|
WO2015051173A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc |
Polynucleotide molecules and uses thereof
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
WO2015058780A1
(en)
|
2013-10-25 |
2015-04-30 |
Biontech Ag |
Method and kit for determining whether a subject shows an immune response
|
|
US20170173128A1
(en)
|
2013-12-06 |
2017-06-22 |
Moderna TX, Inc. |
Targeted adaptive vaccines
|
|
US20150167017A1
(en)
|
2013-12-13 |
2015-06-18 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
US20170007776A1
(en)
|
2014-02-05 |
2017-01-12 |
Biontech Ag |
Cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
WO2015172843A1
(en)
|
2014-05-16 |
2015-11-19 |
Biontech Diagnostics Gmbh |
Methods and kits for the diagnosis of cancer
|
|
WO2016062323A1
(en)
|
2014-10-20 |
2016-04-28 |
Biontech Ag |
Methods and compositions for diagnosis and treatment of cancer
|
|
EP4023755B1
(en)
|
2014-12-12 |
2023-04-26 |
CureVac SE |
Artificial nucleic acid molecules for improved protein expression
|
|
BR112017009835A2
(pt)
|
2014-12-30 |
2017-12-26 |
Curevac Ag |
moléculas de ácido nucleico artificiais
|
|
WO2016155809A1
(en)
|
2015-03-31 |
2016-10-06 |
Biontech Rna Pharmaceuticals Gmbh |
Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
|